Cizumab 100mg Injection

Cizumab 100mg Injection is a type of chemotherapy medication used in the treatment of several types of cancer, such as colorectal cancer, rectal cancer, non-small cell lung cancer, kidney cancer, ovarian cancer, cervical cancer, and brain tumors. The medication's active ingredient is Bevacizumab, which belongs to the drug class of monoclonal antibodies, specifically VEGF (vascular endothelial growth factor) inhibitors. It works by blocking the growth of new blood vessels that feed the tumor. The dosage and duration is correctly administered by the healthcare professional to ensure safe and effective treatment.

• Colorectal Cancer
• Rectal Cancer
• Non-small cell lung Cancer
• Kidney Cancer 
• Ovarian Cancer
• Cervical Cancer
• Brain tumor

Cizumab 100mg Injection caused side effects; some patients may resolve on their own, and some need proper medical attention to recover. Common ones include:

• Numbness in hands or feet
• Weakness and lack of energy
• Diarrhea, nausea, vomiting, abdominal pain
• Constipation
• Loss of appetite
• Weight loss
• Headache
• Vision changes
• Confusion
• Severe allergic reactions
• High Blood pressure
• Delayed wound healing following surgery
• Protein in urine
• Severe infections
• Decrease in counts of white blood cells
• Fever
• Dry skin
• Back pain

Cizumab 100mg Injection should be given as an intravenous (IV) infusion into a vein. It should be injected into the thigh and stomach. Never skip or overdose on the medication, as this can negatively impact the treatment. The medication should be taken under the strict supervision of a doctor to ensure safe treatment. Improper use may affect the effectiveness of the therapy and increase the risk of serious side effects or complications.

Cizumab 100mg Injection is an anti-cancer medication. It works as a targeted therapy in the treatment of various advanced cancers. The medicine contains a VEGF (vascular endothelial growth factor) inhibitor that directly attacks VEGF, which is responsible for the production of tumors and stops the formation of blood vessels that bring oxygen and nutrients to cancerous cells. This helps in slowing tumor growth and can improve the effectiveness of the other cancer treatment.

• ·Kazazi-Hyseni, F., Beijnen, J. H., & Schellens, J. H. (2010). Bevacizumab. The oncologist, 15(8), 819. https://pmc.ncbi.nlm.nih.gov/articles/PMC3825300/
• Braghiroli, M. I., Sabbaga, J., & Hoff, P. M. (2012). Bevacizumab: overview of the literature. Expert review of anticancer therapy, 12(5), 567-580. https://pubmed.ncbi.nlm.nih.gov/22594892/
• Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020). Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer treatment reviews, 86, 102017. https://pubmed.ncbi.nlm.nih.gov/32335505/
• Ellis, L. M., & Kirkpatrick, P. (2005). Bevacizumab. Nature reviews Drug discovery, 4. https://pubmed.ncbi.nlm.nih.gov/15645606/
• Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature reviews Drug discovery, 3(5), 391-400. https://pubmed.ncbi.nlm.nih.gov/15136787/